OTC Markets EXMKT - Delayed Quote USD
Statera Biopharma, Inc. (STAB)
At close: November 6 at 3:00 PM EST
Breakdown
TTM
12/31/2021
12/31/2020
12/31/2019
Cost of Revenue
1,096.3480
488.3140
--
--
Gross Profit
-1,096.3480
-488.3140
--
--
Operating Expense
18,883.1670
28,829.5060
10,909.1670
2,814.1760
Operating Income
-19,979.5150
-29,317.8200
-10,909.1670
-2,814.1760
Net Non Operating Interest Income Expense
-4,690.4720
-4,560.1470
-1,130.6930
-124.2330
Other Income Expense
-67,187.5350
-67,997.1990
-580.0010
-285.6130
Pretax Income
-91,857.5220
-101,875.1660
-12,619.8610
-3,224.0220
Net Income Common Stockholders
-91,832.6150
-101,850.8180
-12,093.8610
-3,224.0220
Diluted NI Available to Com Stockholders
-91,832.6150
-101,850.8180
-12,093.8610
-3,224.0220
Basic EPS
-2.36
-2.90
-0.47
-0.13
Diluted EPS
-2.36
-2.90
-0.47
-0.13
Basic Average Shares
48,036.7640
35,110.3360
25,649.8990
25,649.8990
Diluted Average Shares
48,036.7640
35,110.3360
25,649.8990
25,649.8990
Total Operating Income as Reported
-88,195.8340
-98,343.8030
-10,501.6680
-2,814.1760
Total Expenses
19,979.5150
29,317.8200
10,909.1670
2,814.1760
Net Income from Continuing & Discontinued Operation
-91,832.6150
-101,850.8180
-12,093.8610
-3,224.0220
Normalized Income
-24,645.0800
-33,853.6200
-11,513.8600
-3,224.0220
Interest Expense
--
--
1,130.6930
124.2330
Net Interest Income
-4,690.4720
-4,560.1470
-1,130.6930
-124.2330
EBIT
-19,169.8510
-29,317.8200
-10,909.1670
-2,814.1760
EBITDA
-18,613.5410
-29,062.2460
-10,908.2200
-2,814.1760
Reconciled Cost of Revenue
1,096.3480
488.3140
--
--
Reconciled Depreciation
556.3100
255.5740
0.9470
--
Net Income from Continuing Operation Net Minority Interest
-91,832.6150
-101,850.8190
-12,093.8610
-3,224.0220
Total Unusual Items Excluding Goodwill
-67,187.5350
-67,997.1990
-580.0010
--
Total Unusual Items
-67,187.5350
-67,997.1990
-580.0010
--
Normalized EBITDA
48,573.9940
38,934.9530
-10,328.2190
-2,814.1760
12/31/2019 - 7/28/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BTAX Biostax Corp.
0.0400
0.00%
BIOAF Bioasis Technologies Inc.
0.0001
0.00%
PKBO Peak Bio, Inc.
0.0700
0.00%
PPCB Propanc Biopharma, Inc.
0.0004
+33.33%
COEP Coeptis Therapeutics Holdings, Inc.
0.2078
+3.38%
BIOV.CN BioVaxys Technology Corp.
0.0750
+7.14%
AKTX Akari Therapeutics, Plc
2.3150
-4.54%
XRTX XORTX Therapeutics Inc.
1.4500
+1.40%
ATXI Avenue Therapeutics, Inc.
2.2400
+0.90%
RGBP Regen BioPharma, Inc.
0.1380
0.00%